Antiproliferative and proapoptotic effects of raloxifene on uterine leiomyomas in postmenopausal women

Stefano Palomba, Francesco Orio, Tiziana Russo, Angela Falbo, Achille Tolino, Gaetano Lombardi, Vincenzo Cimini, Fulvio Zullo

Research output: Contribution to journalArticle

Abstract

Objective: To study the cell effects of raloxifene on uterine and leiomyoma tissue in postmenopausal women. Design: Prospective, randomized, double-blind, placebo-controlled study. Setting: Department of Obstetrics and Gynecology, University "Magna Graecia" of Catanzaro, Italy. Patient(s): Forty postmenopausal women affected by uterine leiomyomas and selected for hysterectomy. Intervention(s): Treatment for three cycles of 28 days with raloxifene at a dose of 180 mg/day orally (raloxifene group) or placebo tablets (3 tablets/day orally) (placebo group). Main Outcome Measure(s): Uterine and leiomyoma dimensions were measured in each subject at entry and before surgery. On leiomyomas and homologous myometrium the proliferating cell nuclear antigen (PCNA)-positive cells/total cells (PCNA/TC) and the Bcl-2-positive cells/Bax-positive cells (Bcl-2/Bax) ratios (%), as proliferation and apoptotic indexes, respectively, were measured. Result(s): After treatment, uterine and leiomyoma sizes were significantly changed in comparison with baseline and the placebo group. PCNA/TC and Bcl-2/Bax ratios were significantly higher in leiomyomas than in homologous myometrium. A significant difference was detected in PCNA/TC between the myometrium of the raloxifene and control groups, whereas no difference was observed in the Bcl-2/Bax ratio. A significant difference in PCNA/TC and Bcl-2/Bax ratios was detected in leiomyoma tissue between the raloxifene group and controls. Conclusion(s): In postmenopausal women, raloxifene administration reduces uterine leiomyomas by exerting a cell antiproliferative and proapoptotic action.

Original languageEnglish
Pages (from-to)154-161
Number of pages8
JournalFertility and Sterility
Volume84
Issue number1
DOIs
Publication statusPublished - Jul 2005

Fingerprint

Leiomyoma
Proliferating Cell Nuclear Antigen
Myometrium
Placebos
Tablets
Raloxifene Hydrochloride
Control Groups
Hospital Obstetrics and Gynecology Department
Hysterectomy
Gynecology
Italy
Outcome Assessment (Health Care)

Keywords

  • Apoptosis
  • Bax
  • Bcl-2
  • Leiomyoma
  • PCNA
  • Raloxifene
  • SERM

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Antiproliferative and proapoptotic effects of raloxifene on uterine leiomyomas in postmenopausal women. / Palomba, Stefano; Orio, Francesco; Russo, Tiziana; Falbo, Angela; Tolino, Achille; Lombardi, Gaetano; Cimini, Vincenzo; Zullo, Fulvio.

In: Fertility and Sterility, Vol. 84, No. 1, 07.2005, p. 154-161.

Research output: Contribution to journalArticle

Palomba, S, Orio, F, Russo, T, Falbo, A, Tolino, A, Lombardi, G, Cimini, V & Zullo, F 2005, 'Antiproliferative and proapoptotic effects of raloxifene on uterine leiomyomas in postmenopausal women', Fertility and Sterility, vol. 84, no. 1, pp. 154-161. https://doi.org/10.1016/j.fertnstert.2004.12.058
Palomba, Stefano ; Orio, Francesco ; Russo, Tiziana ; Falbo, Angela ; Tolino, Achille ; Lombardi, Gaetano ; Cimini, Vincenzo ; Zullo, Fulvio. / Antiproliferative and proapoptotic effects of raloxifene on uterine leiomyomas in postmenopausal women. In: Fertility and Sterility. 2005 ; Vol. 84, No. 1. pp. 154-161.
@article{30cf90b0501741fba2cc23f5e78bc2ec,
title = "Antiproliferative and proapoptotic effects of raloxifene on uterine leiomyomas in postmenopausal women",
abstract = "Objective: To study the cell effects of raloxifene on uterine and leiomyoma tissue in postmenopausal women. Design: Prospective, randomized, double-blind, placebo-controlled study. Setting: Department of Obstetrics and Gynecology, University {"}Magna Graecia{"} of Catanzaro, Italy. Patient(s): Forty postmenopausal women affected by uterine leiomyomas and selected for hysterectomy. Intervention(s): Treatment for three cycles of 28 days with raloxifene at a dose of 180 mg/day orally (raloxifene group) or placebo tablets (3 tablets/day orally) (placebo group). Main Outcome Measure(s): Uterine and leiomyoma dimensions were measured in each subject at entry and before surgery. On leiomyomas and homologous myometrium the proliferating cell nuclear antigen (PCNA)-positive cells/total cells (PCNA/TC) and the Bcl-2-positive cells/Bax-positive cells (Bcl-2/Bax) ratios ({\%}), as proliferation and apoptotic indexes, respectively, were measured. Result(s): After treatment, uterine and leiomyoma sizes were significantly changed in comparison with baseline and the placebo group. PCNA/TC and Bcl-2/Bax ratios were significantly higher in leiomyomas than in homologous myometrium. A significant difference was detected in PCNA/TC between the myometrium of the raloxifene and control groups, whereas no difference was observed in the Bcl-2/Bax ratio. A significant difference in PCNA/TC and Bcl-2/Bax ratios was detected in leiomyoma tissue between the raloxifene group and controls. Conclusion(s): In postmenopausal women, raloxifene administration reduces uterine leiomyomas by exerting a cell antiproliferative and proapoptotic action.",
keywords = "Apoptosis, Bax, Bcl-2, Leiomyoma, PCNA, Raloxifene, SERM",
author = "Stefano Palomba and Francesco Orio and Tiziana Russo and Angela Falbo and Achille Tolino and Gaetano Lombardi and Vincenzo Cimini and Fulvio Zullo",
year = "2005",
month = "7",
doi = "10.1016/j.fertnstert.2004.12.058",
language = "English",
volume = "84",
pages = "154--161",
journal = "Fertility and Sterility",
issn = "0015-0282",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Antiproliferative and proapoptotic effects of raloxifene on uterine leiomyomas in postmenopausal women

AU - Palomba, Stefano

AU - Orio, Francesco

AU - Russo, Tiziana

AU - Falbo, Angela

AU - Tolino, Achille

AU - Lombardi, Gaetano

AU - Cimini, Vincenzo

AU - Zullo, Fulvio

PY - 2005/7

Y1 - 2005/7

N2 - Objective: To study the cell effects of raloxifene on uterine and leiomyoma tissue in postmenopausal women. Design: Prospective, randomized, double-blind, placebo-controlled study. Setting: Department of Obstetrics and Gynecology, University "Magna Graecia" of Catanzaro, Italy. Patient(s): Forty postmenopausal women affected by uterine leiomyomas and selected for hysterectomy. Intervention(s): Treatment for three cycles of 28 days with raloxifene at a dose of 180 mg/day orally (raloxifene group) or placebo tablets (3 tablets/day orally) (placebo group). Main Outcome Measure(s): Uterine and leiomyoma dimensions were measured in each subject at entry and before surgery. On leiomyomas and homologous myometrium the proliferating cell nuclear antigen (PCNA)-positive cells/total cells (PCNA/TC) and the Bcl-2-positive cells/Bax-positive cells (Bcl-2/Bax) ratios (%), as proliferation and apoptotic indexes, respectively, were measured. Result(s): After treatment, uterine and leiomyoma sizes were significantly changed in comparison with baseline and the placebo group. PCNA/TC and Bcl-2/Bax ratios were significantly higher in leiomyomas than in homologous myometrium. A significant difference was detected in PCNA/TC between the myometrium of the raloxifene and control groups, whereas no difference was observed in the Bcl-2/Bax ratio. A significant difference in PCNA/TC and Bcl-2/Bax ratios was detected in leiomyoma tissue between the raloxifene group and controls. Conclusion(s): In postmenopausal women, raloxifene administration reduces uterine leiomyomas by exerting a cell antiproliferative and proapoptotic action.

AB - Objective: To study the cell effects of raloxifene on uterine and leiomyoma tissue in postmenopausal women. Design: Prospective, randomized, double-blind, placebo-controlled study. Setting: Department of Obstetrics and Gynecology, University "Magna Graecia" of Catanzaro, Italy. Patient(s): Forty postmenopausal women affected by uterine leiomyomas and selected for hysterectomy. Intervention(s): Treatment for three cycles of 28 days with raloxifene at a dose of 180 mg/day orally (raloxifene group) or placebo tablets (3 tablets/day orally) (placebo group). Main Outcome Measure(s): Uterine and leiomyoma dimensions were measured in each subject at entry and before surgery. On leiomyomas and homologous myometrium the proliferating cell nuclear antigen (PCNA)-positive cells/total cells (PCNA/TC) and the Bcl-2-positive cells/Bax-positive cells (Bcl-2/Bax) ratios (%), as proliferation and apoptotic indexes, respectively, were measured. Result(s): After treatment, uterine and leiomyoma sizes were significantly changed in comparison with baseline and the placebo group. PCNA/TC and Bcl-2/Bax ratios were significantly higher in leiomyomas than in homologous myometrium. A significant difference was detected in PCNA/TC between the myometrium of the raloxifene and control groups, whereas no difference was observed in the Bcl-2/Bax ratio. A significant difference in PCNA/TC and Bcl-2/Bax ratios was detected in leiomyoma tissue between the raloxifene group and controls. Conclusion(s): In postmenopausal women, raloxifene administration reduces uterine leiomyomas by exerting a cell antiproliferative and proapoptotic action.

KW - Apoptosis

KW - Bax

KW - Bcl-2

KW - Leiomyoma

KW - PCNA

KW - Raloxifene

KW - SERM

UR - http://www.scopus.com/inward/record.url?scp=22244479042&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22244479042&partnerID=8YFLogxK

U2 - 10.1016/j.fertnstert.2004.12.058

DO - 10.1016/j.fertnstert.2004.12.058

M3 - Article

C2 - 16009171

AN - SCOPUS:22244479042

VL - 84

SP - 154

EP - 161

JO - Fertility and Sterility

JF - Fertility and Sterility

SN - 0015-0282

IS - 1

ER -